Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (February 2025)
31 slides from Sutro Biopharma's investor presentation, February 2025
Slide 1: Science Designed to Provide Endless Possibility
Science Designed to Provide Endless Possibility February 2025 Sutro Biopharma NASDAQ: STRO 1 NON CONFIDENTIAL
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than sta
Slide 3: Advancing Next-Generation ADCs with Proprietary Cell-free XpressCF Discovery Platform
3 Advancing Next-Generation ADCs with Proprietary Cell-free XpressCF® Discovery Platform Pipeline Luvelta: potential best-in-class tubulin inhibitor ADC for a range of FRα expressing cancers • Two registrational trials ongoing and multiple follow-on opportunities Proprietary Cell-free STRO-004 and N
Slide 4: Significant Near- and Long-term Opportunities for Broad Pipeline of Precisely Designed ADCs
Significant Near- and Long-term Opportunities for Broad Pipeline of Precisely Designed ADCs Luvelta Next-Generation ADCs: Pipeline-in-a-Product Potential Delivering Three INDs Over Next Three Years Lead Opportunity: Ovarian Cancer (Fast Track Designation) Three-pronged R&D strategy to enhance ADCs’
Slide 5: Well Capitalized with Strong Business Development Track Record Validating Cell-Free Platform
5 Well Capitalized with Strong Business Development Track Record Validating Cell-Free Platform in cash, cash equivalents & Funding generated from our (1) ~$388M marketable securities (2) ~$975M collaborators Over $2 Billion Potential Future Milestones plus Royalties Phase 2/3 vaccines for invasive P
Slide 6: Luveltamab Tazevibulin (Luvelta)
Luveltamab Tazevibulin (Luvelta) 6 NON CONFIDENTIAL
Slide 7: Luvelta: Precisely Designed Tubulin Inhibitor ADC with Potential to Address a Broader Patient Population
Luvelta: Precisely Designed Tubulin Inhibitor ADC with Potential to Address a Broader Patient Population of FRα-expressing Cancers Key Features Driving Luvelta’s Best-in-class Potential Receptor Hemiasterlin payload internalization • Tubulin inhibitor • High potency & ICD • High bystander killing •
Slide 8: Luvelta: Promising Clinical Activity in All FRα-Expressing Indications Evaluated
Luvelta: Promising Clinical Activity in All FRα-Expressing Indications Evaluated Estimated Annual Incidence in FRα-Expressing Patient Populations (U.S., Europe and Japan) Ovarian Cancer: ~69K NSCLC, Adenocarcinoma: ~108K Status: REFRαME-O1 Registrational Study Status: Phase 2 initial data expected 2
Slide 9: Luvelta: Opportunity to be First Therapy for ~80% of PROC Patient Population
Luvelta: Opportunity to be First Therapy for ~80% of PROC Patient Population with Lower TPS≥25% Threshold Luvelta Potentially Doubles the Addressable PROC Patients Patients with Platinum-Resistant Ovarian Cancer 80% • Luvelta has demonstrated clinical activity in PROC patients with FRα ≥25% of any s
Slide 10: Significant Opportunity for Luvelta to Become Best-in-Class, With Clear Commercial Path
Significant Opportunity for Luvelta to Become Best-in-Class, With Clear Commercial Path Approved FRα ADC Luvelta Addressable 35% of PROC patients 2 80% of PROC patients 1 Patient (TPS of ≥75% FRα, 2+ TPS ≥25% FRα at any Luvelta: Population staining intensity) staining intensity Tolerability Black bo
Slide 11: Registrational Strategy Supported by Clinical Data from ~100 Patients
Registrational Strategy Supported by Clinical Data from ~100 Patients Maximum Reduction in Tumor Target Lesions in RECIST-Evaluable Patients (N=92 Evaluable) 20% 3 in 5.2, 2 in 4.3, 2 in <=2.9, and 1 in >=5.6mg/kg -30% Partial response Ovarian Cancer Patients Total (N = 99) Platinum Sensitive 21 (21
Slide 12: REFRαME-O1: Registration-directed Study for Patients with PROC
REFRαME-O1: Registration-directed Study for Patients with PROC Phase 2 Dose Finding: • 32% ORR in evaluable patients at the 5.2 mg/kg starting dose* – the selected dose for the randomized portion • Neutropenia well-managed; no new safety findings Phase 3 Randomized Portion of the Trial: Ongoing • Po
Slide 13: REFRαME-O1 Enrollment Progressing Ahead of Internal Projections
REFRαME-O1 Enrollment Progressing Ahead of Internal Projections Active Countries Planned Countries* Trial Sites/Enrollment Austria Italy Australia Phase 3 randomized part 2 Belgium Poland enrollment tracking ahead of Canada internal projections Bulgaria Spain Isr ael Czech Republic Sweden Over 200 s
Slide 14: REFRαME-O1 Dose Optimization: Confirms Luvelta's Robust Response in PROC Patients
REFRαME-O1 Dose Optimization: Confirms Luvelta’s Robust Response in PROC Patients with FRα ≥25%, Selected Starting Dose of 5.2 mg/kg Topline Results from Efficacy Evaluable Patients (5.2 mg/kg group; N = 25)* Patient Profile Efficacy Profile Safety Profile • ~1/2 of the patients treated were • Achie
Slide 15: REFRαME-P1: Registrational Trial Addressing Unmet Pediatric Need
REFRαME-P1: Registrational Trial Addressing Unmet Pediatric Need, Enabling Potential for Priority Review Voucher • Pediatric RAM AML – devastating disease impacting infants and toddlers; overall survival of 15-30% • Regulatory submission requirements in U.S. and Europe may accelerate PROC submission
Slide 16: Luvelta Demonstrated Compelling Anti-Tumor Activity in Lower and Variable FRα Expressing Tumors
Luvelta Demonstrated Compelling Anti-Tumor Activity and Manageable Safety Profile In Lower and Variable FRα Expressing Tumors Bevacizumab Combo in Ovarian Cancer RAM AML1 NSCLC N = 17 N = 25 Preclinical Median PFS 8.3 months; 55.6% ORR at RP2D Meaningful clinical responses, including complete Single
Slide 17: STRO-004 & Next-Gen ADCs
STRO-004 & Next-Gen ADCs Leveraging Cell-Free Platform to Deliver Three INDs Over the Next Three Years 17 NON CONFIDENTIAL
Slide 18: Wider Therapeutic Index Achieved with Sutro's Cell-free ADC Platform
Wider Therapeutic Index Achieved with Sutro’s Cell-free ADC Platform Key Sutro Technologies to Improve ADCs Outside the Tumor Linker & payload design MTD ADC Click chemistry Site specific conjugation MTD ADC Antibody engineering TI TI MED ADC Focused R&D Strategy – Make ADCs Better Inside the Tumor
Slide 19: XpressCF Platform has Unique ADC Performance Capabilities Over Other Topo1 ADC Platforms
XpressCF® Platform has Unique ADC Performance Capabilities Over Other Topo1 ADC Platforms Beta-Glu ADC2/ iADC/ Site HT DAR>8 Fc Silent Bispecific Linker Dual LPs iSAC Specific Screening Abbvie AstraZeneca Daiichi Sankyo Dualitybio Genequantum Genmab Gilead Hansoh Hengrui Kelun Lilly Medilink Merck K
Slide 20: STRO-004: Next Generation Tissue Factor-Targeting Exatecan/Topo1 ADC
STRO-004: Next Generation Tissue Factor-Targeting Exatecan/Topo1 ADC with Enhanced Therapeutic Potential Optimally Designed for Improved Clinical Benefits, Increased Tolerability Leads Enhanced Stability, Potency and Tumor Selectivity to Enhanced Drug Exposure • Exatecan payload: Clinically validate
Slide 21: Tissue Factor is Broadly Expressed Across Multiple Solid Tumor Indications
Tissue Factor is Broadly Expressed Across Multiple Solid Tumor Indications, Presenting Opportunity for Pan-Tumor Targeting Broad Opportunity for TF in Many Solid Tumors of Significant Unmet Need • TF expression has been associated with poor disease prognosis and increased metastatic properties • Cli
Slide 22: STRO-004 DAR8 Exatecan Achieved Sustained Tumor Regressions in Xenograft Models
STRO-004 DAR8 Exatecan Achieved Sustained Tumor Regressions in Xenograft Models of NSCLC and HNSCC at Low Doses Lung (TF+++) Head and Neck (TF++) H1975 Growth Curves Detroit562 Growth Curves 1500 1500 (mm3)3) (mm33)) 1250 1250 Volume(mm volume(mm 1000 1000 Tumor Volume TumorVolume 750 750 500 500 Tu
Slide 23: STRO-004 Demonstrated Reduced Platform and On-target Toxicity
STRO-004 Demonstrated Reduced Platform and On-target Toxicity Due to Site Specific Conjugation and Beta Glu Linker-Payload Technology STRO-004 Tolerability Profile vs. Approved aTF ADC Eye Inflammation Skin Toxicities STRO-004 (DAR8-exatecan) Approved aTF ADC (DAR4-MMAE) 23 NON CONFIDENTIAL
Slide 24: Dual-Payload ADCs: Combining Payloads to Overcome Resistance
Dual-Payload ADCs: Combining Payloads to Overcome Resistance Potential Advantages of Dual-Payload ADC Approach Reduced Toxicity Reduced Clinical Complexity Simultaneous Payload Delivery Overcome Resistance Mechanisms 24 NON CONFIDENTIAL
Slide 25: Dual Payload ADC (Topo1i + anti-Tubulin) Displayed Enhanced In Vivo Efficacy in Ovarian Cancer
Dual Payload ADC (Topo1i + anti-Tubulin) Displayed Enhanced In Vivo Efficacy in Ovarian Cancer IGROV-1 - Tumor Growth IGROV-1 - Survival IGROV-1 - Time to Tumor Quadrupling Relative Tumor Volume (%) 1500 100 100 Percent Survival Percent survival 75 75 1000 50 50 500 25 25 0 0 0 0 20 40 60 80 100 0 2
Slide 26: Dual-Payload Topo1i + PARPi ADC Showed Increased Activity Compared to Topo1i ADC
Dual-Payload Topo1i + PARPi ADC Showed Increased Activity Compared to Topo1i ADC MC38-hTF MC38-hTF in vitro potency in vivo anti-tumor activity DAR2 PARPi ADC Vehicle (PBS) DAR4 Topo1i ADC 5 mg/kg DAR4 Topo1i ADC DAR4 Topo1i + DAR2 PARPi ADC2 5 mg/kg DAR4 Topo1i + DAR2 PARPi ADC 2 PBS – phosphate bu
Slide 27: iADC: Combines Tumor-Targeted Delivery of a Cytotoxin and Immune Stimulator
iADC: Combines Tumor-Targeted Delivery of a Cytotoxin and Immune Stimulator Strategic Partnership with Astellas to Deliver a New Treatment Option for Cold Tumors and Patients Unresponsive to Existing Cancer Immunotherapies Combining a cytotoxin and immune modulator gives potential to: • Act alone by
Slide 28: Novel Mechanism of Action Differentiates iADC from Other Immunotherapies
Novel Mechanism of Action Differentiates iADC from Other Immunotherapies Sutro iADCs bridge innate and adaptive immunity to provide broad Sutro STING / PD-1 / CAR-T protection in a single molecule ISAC Vaccine iADC TLR PDL-1 Cells Molecule Targeted and Chemo Mixed ADC Ab Biologic Biologic homogeneou
Slide 29: Boehringer Ingelheim BioXcellence Collaboration: First-in-class Cell-free Manufacturing at Commercial Scale
29 Boehringer Ingelheim BioXcellence Collaboration: Established First-in-class Cell-free Manufacturing Capabilities at Commercial Scale First-ever manufacturing of a cell-free ADC to large-scale GMP production, marking an industry milestone Proprietary Cell-free XpressCF® Platform Advantages: • Modu
Slide 30: Broad Pipeline Driven by Cell-free Technology
Broad Pipeline Driven by Cell-free Technology WORLDWIDE OR PHASE 3/ GEOGRAPHIC PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL PARTNER SUTRO-LED PROGRAMS Ovarian Cancer Ovarian Cancer Luveltamab (bevacizumab combo) tazevibulin FRα Antibody-Drug Endometrial
Slide 31: Experienced Leadership Team
Experienced Leadership Team William Newell, JD Anne Borgman, MD Barbara Leyman, PhD Ed Albini, MBA Chief Executive Officer and Chief Medical Officer Chief Business Development Officer Chief Financial Officer Member of the Board of Directors Hans-Peter Gerber, PhD Jane Chung, RPh Linda Fitzpatrick Ve
Sutro Biopharma — Investor Presentation (February 2025) on 6ix